Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B61: Pembrolizumab + Lenvatinib in First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
2023-504944-32-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in non-clear cell renal cell carcinoma (nccRCC), sponsored by Merck & Co. Primary endpoint: Objective Response Rate (ORR). Started Feb 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on 2023-504944-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504944-32-00.